(August 30, 2018) Researchers at Brigham and Women’s Hospital in Boston have found new clues to the origin of high-grade serous carcinoma (HGSC). The majority of women who are diagnosed with ovarian cancer have HGSC, and up to 90 percent of those cases go undetected and undiagnosed until the cancer has spread. Previous studies showed the … Continued
(August 24, 2018) A recent study, published in JAMA Oncology, shed light on non-BRCA gene associations to breast and ovarian cancers. Researchers discovered new genes and confirmed previously existing evidence by conducting a whole-exome analysis of 11,416 patients with breast, ovarian, or both cancers and compared them with 3,988 people in a control group in … Continued
(August 23, 2018) Researchers from Vanderbilt Institute for Clinical and Translational Research recently conducted a study which focused on Medicare Part B recipients, those above the age of 65 or disabled, who were eligible for genetic testing. More specifically, they looked at women who had been seen at health centers in the Southeast United States … Continued
(August 22, 2018) Several institutions in the UK recently published their project on finding patterns in DNA mutations. The tumors of 117 women, all of whom were diagnosed with high grade serous ovarian cancer, were processed by computer algorithms. Rather than looking at mutations within each DNA strand, the algorithm identified seven patterns of DNA … Continued
(July 30, 2018) Recently, two retrospective studies were published about the effects of analgesics, or pain relievers, on ovarian cancer. The information is actually a culmination of two studies, both of which have led researchers to believe that there is an association between regular use of analgesics and both reduced risk of, and increased survival … Continued
You may have seen headlines in April 2023 about Johnson & Johnson paying nearly $9 billion to tens of thousands of people who claim talcum powder caused their cancer, including ovarian cancer. Controversy around the connection between talcum powder and cancer has gone on for years and has generated thousands of lawsuits. Ovarian Cancer Research Alliance provides information … Continued
(July 12, 2018) A study involving 58,472 women between 1994 and 2015 concluded that assisted reproductive treatment, or ART, did not lead to an increased risk of ovarian cancer. Originally it was thought that the hormones used in ART would increase ovarian activity, which would in turn increase one’s risk of ovarian cancer. However, data … Continued
(July 2, 2018) Last month the American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, IL. Thirty nine thousand people from around the world attend to learn about the latest in cancer research. Ovarian cancer survivor and research advocate Annie Ellis attended the meeting and wrote a report highlighting some of the … Continued
(June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery. A phase III trial studied 1,873 women who had not had any prior treatments for stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. Once the women had undergone … Continued
(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from ovarian cancer researchers such as Dr. Anil Sood of MD Anderson and Dr. Dineo Khabele of … Continued
(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed by hormone replacement therapy (HRT). Eight hundred and seventy two women were followed for around 7.5 years … Continued
(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued
Get email updates about research news, action alerts, and ways to join the fight.
